BR112017011335A2 - compostos de 4h-pirido[1,2-a]pirimidin-4-ona - Google Patents
compostos de 4h-pirido[1,2-a]pirimidin-4-onaInfo
- Publication number
- BR112017011335A2 BR112017011335A2 BR112017011335-0A BR112017011335A BR112017011335A2 BR 112017011335 A2 BR112017011335 A2 BR 112017011335A2 BR 112017011335 A BR112017011335 A BR 112017011335A BR 112017011335 A2 BR112017011335 A2 BR 112017011335A2
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- pyrido
- pyrimidin
- agents
- processes
- Prior art date
Links
- NYJWYCAHJRGKMI-UHFFFAOYSA-N pyrido[1,2-a]pyrimidin-4-one Chemical class C1=CC=CN2C(=O)C=CN=C21 NYJWYCAHJRGKMI-UHFFFAOYSA-N 0.000 title 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
- C07F1/08—Copper compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F3/00—Compounds containing elements of Groups 2 or 12 of the Periodic Table
- C07F3/06—Zinc compounds
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
a presente invenção diz respeito a compostos da fórmula i ou ii; processos (i), (ii) para sua preparação e seu uso como agentes ou composições farmacêuticas no tratamento de distúrbios neurológicos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2014904868A AU2014904868A0 (en) | 2014-12-02 | 4H-PYRIDO[1,2-a]PYRIMIDIN-4-ONE COMPOUNDS | |
AU2014904868 | 2014-12-02 | ||
PCT/AU2015/000730 WO2016086261A1 (en) | 2014-12-02 | 2015-12-02 | 4H-PYRIDO[1,2-a]PYRIMIDIN-4-ONE COMPOUNDS |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112017011335A2 true BR112017011335A2 (pt) | 2018-02-20 |
Family
ID=56090727
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112017011335-0A BR112017011335A2 (pt) | 2014-12-02 | 2015-12-02 | compostos de 4h-pirido[1,2-a]pirimidin-4-ona |
Country Status (10)
Country | Link |
---|---|
US (4) | US10287285B2 (pt) |
EP (1) | EP3227292B1 (pt) |
JP (2) | JP6784942B2 (pt) |
KR (1) | KR20170088851A (pt) |
CN (2) | CN107001360B (pt) |
AU (2) | AU2015358284B2 (pt) |
BR (1) | BR112017011335A2 (pt) |
CA (1) | CA2968090A1 (pt) |
EA (1) | EA031505B1 (pt) |
WO (1) | WO2016086261A1 (pt) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017040879A1 (en) * | 2015-09-04 | 2017-03-09 | Lysosomal Therapeutics Inc. | Thiazolo(3,2-a) pyrimidinone and other heterobicyclic pyrimidinone compounds for use in medical therapy |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4022897A (en) * | 1974-03-04 | 1977-05-10 | E. R. Squibb & Sons, Inc. | CNS active compounds |
US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
US4160452A (en) | 1977-04-07 | 1979-07-10 | Alza Corporation | Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina |
HU178910B (en) * | 1977-08-19 | 1982-07-28 | Chinoin Gyogyszer Es Vegyeszet | Process for preparing 2,3-disubstituted-4-oxo-4h-pyrido/1,2-a/-pyrimidines |
US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
AU2002951868A0 (en) * | 2002-10-04 | 2002-10-24 | Prana Biotechnology Limited | Compound i |
EP2210892A3 (en) * | 2002-10-04 | 2010-10-27 | Prana Biotechnology Limited | Neurologically-active compounds |
AR054438A1 (es) * | 2005-04-15 | 2007-06-27 | Kudos Pharm Ltd | Inhibidores de adn -pk |
ZA200809493B (en) * | 2006-04-14 | 2010-08-25 | Prana Biotechnology Ltd | Method of treatment of age-related macular degeneration (AMD) |
CN101589026B (zh) * | 2006-06-22 | 2013-10-16 | 普拉纳生物技术有限公司 | 治疗脑神经胶质瘤的方法 |
CN103983627A (zh) * | 2008-06-17 | 2014-08-13 | 韩国巴斯德研究所 | 作为抗结核病药的吡啶并嘧啶化合物 |
EP2157433A1 (en) | 2008-08-18 | 2010-02-24 | Centre National De La Recherche Scientifique (Cnrs) | New method for identifying compounds useful for treating and/or preventing diseases associated with bone loss |
WO2010136778A1 (en) * | 2009-05-29 | 2010-12-02 | Kudos Pharmaceuticals Limited | Dibenzothiophene derivatives as dna- pk inhibitors |
EP2523956A1 (en) * | 2010-01-13 | 2012-11-21 | Institut Pasteur Korea | Anti - infective pyrido (1,2 -a) pyrimidines |
-
2015
- 2015-12-02 AU AU2015358284A patent/AU2015358284B2/en not_active Ceased
- 2015-12-02 US US15/529,891 patent/US10287285B2/en not_active Expired - Fee Related
- 2015-12-02 CN CN201580063673.4A patent/CN107001360B/zh not_active Expired - Fee Related
- 2015-12-02 BR BR112017011335-0A patent/BR112017011335A2/pt not_active Application Discontinuation
- 2015-12-02 JP JP2017529392A patent/JP6784942B2/ja active Active
- 2015-12-02 WO PCT/AU2015/000730 patent/WO2016086261A1/en active Application Filing
- 2015-12-02 CN CN202010904358.2A patent/CN111961050A/zh active Pending
- 2015-12-02 KR KR1020177013830A patent/KR20170088851A/ko not_active Application Discontinuation
- 2015-12-02 EA EA201790795A patent/EA031505B1/ru unknown
- 2015-12-02 EP EP15865227.1A patent/EP3227292B1/en active Active
- 2015-12-02 CA CA2968090A patent/CA2968090A1/en not_active Abandoned
-
2019
- 2019-05-10 US US16/409,296 patent/US10738050B2/en active Active
-
2020
- 2020-06-24 US US16/910,896 patent/US11008319B2/en active Active
- 2020-09-25 AU AU2020239797A patent/AU2020239797A1/en not_active Abandoned
- 2020-10-07 JP JP2020169555A patent/JP2021011492A/ja not_active Ceased
-
2021
- 2021-04-07 US US17/224,512 patent/US20210230159A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US11008319B2 (en) | 2021-05-18 |
CN111961050A (zh) | 2020-11-20 |
AU2015358284B2 (en) | 2020-07-02 |
US20170267676A1 (en) | 2017-09-21 |
AU2020239797A1 (en) | 2020-10-29 |
EP3227292B1 (en) | 2022-03-09 |
US20210230159A1 (en) | 2021-07-29 |
EA031505B1 (ru) | 2019-01-31 |
US10287285B2 (en) | 2019-05-14 |
JP2017537108A (ja) | 2017-12-14 |
EP3227292A4 (en) | 2018-06-13 |
CN107001360B (zh) | 2020-09-18 |
US20200317670A1 (en) | 2020-10-08 |
KR20170088851A (ko) | 2017-08-02 |
CA2968090A1 (en) | 2016-06-09 |
CN107001360A (zh) | 2017-08-01 |
EA201790795A1 (ru) | 2017-07-31 |
EP3227292A1 (en) | 2017-10-11 |
JP6784942B2 (ja) | 2020-11-18 |
AU2015358284A1 (en) | 2017-06-15 |
JP2021011492A (ja) | 2021-02-04 |
WO2016086261A1 (en) | 2016-06-09 |
US20190352301A1 (en) | 2019-11-21 |
US10738050B2 (en) | 2020-08-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2018001089A1 (es) | Sales de valbenazina y polimorfos de las mismas. | |
CY1121170T1 (el) | Νεες ενωσεις ως ρυθμιστες πρωτεϊνικων κινασων | |
DOP2019000055A (es) | Compuestos y composiciones como inhibidores de los receptores endosomales tipo peaje | |
NI201600144A (es) | Derivados de quinoxalina utiles como moduladores del fgfr cinasa | |
BR112016025423A2 (pt) | compostos e composições como agonistas de receptores do tipo toll 7 | |
CL2016001895A1 (es) | Compuestos | |
BR112015032546A2 (pt) | derivados de pirrolo[3,2-d]pirimidina para o tratamento de infecções virais e outras doenças | |
BR112016025048A2 (pt) | compostos e composições como agonistas do receptor tipo toll7 | |
WO2015153959A3 (en) | Small molecule inhibitors of mcl-1 and uses thereof | |
EA201590663A1 (ru) | ПРОИЗВОДНЫЕ ПИРРОЛО[3,2-d]ПИРИМИДИНА ДЛЯ ЛЕЧЕНИЯ ВИРУСНЫХ ИНФЕКЦИЙ И ДРУГИХ ЗАБОЛЕВАНИЙ | |
CO2018013803A2 (es) | 1h-pirazolo[4,3-b]piridinas como inhibidores de pde1 | |
CL2014001103A1 (es) | Compuestos derivados de heteroaril piridona y aza-piridona sustituidas, inhibidores de btk quinasa; composicion farmaceutica que los comprende; proceso de preparacion de la composicion farmaceutica; kit farmaceutico; y uso para el tratamiento de trastornos inmunes, cancer, inflamacion, trastornos neurologicos, entre otros. | |
UY35115A (es) | Imidazo[1,2-a]piridincarboxamidas aminosustituidas y su uso | |
PH12017500401A1 (en) | Therapeutic compounds as inhibitors of the orexin-1 receptor | |
DK3489238T3 (da) | Farmaceutiske sammensætninger af 6h-pyrido[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5-on- og [1,2,4]triazolo[1,5-c]pteridin-5(6h)-on-derivater som pde1-inhibitorer til behandling af for eksempel neurologiske lidelser | |
CO7111276A2 (es) | Compuestos de 3,5 disustituido-3h imidazo[4,5-b] piridina y 3,5 disustituido - 3h-[1,2,3] triaolo [4,5-b] piridina novedosos como moduladores d proteínas cinasas c-met | |
BR112016029825A2 (pt) | composto | |
SV2018005753A (es) | 1,5-dihidro-4h-pirazolo[3,4-d]pirimidin-4-onas y 1,5-dihidro-4h-pirazolo[4,3-c]piridin-4-onas como inhibidores de pde1 | |
ECSP19043790A (es) | Pirazolo[3,4-b]piridinas e imidazo[1,5-b]piridazinas como inhibidores de PDE1 | |
UY35747A (es) | Derivados sustituidos de fenilalanina | |
MY201535A (en) | Therapeutic compounds | |
GT201400161A (es) | Fenilimidazopirazoles sustituidos y su uso | |
DOP2017000018A (es) | [1,2,4]triazolo[4,3-b]piridazinas para su uso en el tratamiento de enfermedades proliferativas | |
WO2014035846A3 (en) | Substituted azaindole compounds, salts, pharmaceutical compositions thereof and methods of use | |
BR112017021583A2 (pt) | métodos para o tratamento de transtornos inflamatórios |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |